Keytruda and mRNA technology show promise in skin cancer treatment trial
A new clinical trial has found that combining Keytruda with a personalized cancer vaccine can significantly reduce the risk of melanoma recurrence and mortality, cutting the risk by 38% over two years compared to using Keytruda alone.


















